Drugging RAS: Know the enemy

The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Science (American Association for the Advancement of Science) 2017-03, Vol.355 (6330), p.1158-1163
Hauptverfasser:	Papke, Bjoern, Der, Channing J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cancer Cell Membrane - enzymology Drug Design Enzyme Inhibitors - chemistry Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Gene mapping Genes Humans Molecular Targeted Therapy Mutants Mutation Neoplasms - drug therapy Neoplasms - genetics New technology Oncogenes Perception ras Proteins - antagonists & inhibitors ras Proteins - genetics REVIEWS Stands Strategy Supports Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!